ImmunityBio Inc (NASDAQ:IBRX) has a beta value of 0.70 and has seen 9.73 million shares traded in the last trading session. The company, currently valued at $2.64B, closed the last trade at $3.62 per share which meant it gained $0.3 on the day or 9.04% during that session. The IBRX stock price is -190.88% off its 52-week high price of $10.53 and 37.02% above the 52-week low of $2.28. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.2 million shares traded. The 3-month trading volume is 5.73 million shares.
The consensus among analysts is that ImmunityBio Inc (IBRX) is Sell stock at the moment, with a recommendation rating of 1.50. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 0 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.13.
ImmunityBio Inc (NASDAQ:IBRX) trade information
Sporting 9.04% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the IBRX stock price touched $3.62 or saw a rise of 7.89%. Year-to-date, ImmunityBio Inc shares have moved 41.41%, while the 5-day performance has seen it change 7.74%. Over the past 30 days, the shares of ImmunityBio Inc (NASDAQ:IBRX) have changed 51.46%. Short interest in the company has seen 55.92 million shares shorted with days to cover at 8.31.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 39.67% from current levels. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the current price level is -65.75% off the targeted high while a plunge would see the stock gain -65.75% from current levels.
ImmunityBio Inc (IBRX) estimates and forecasts
The company’s shares have lost -6.70% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 3,312.86%.
4 analysts offering their estimates for the company have set an average revenue estimate of 9.51M for the current quarter. 2 have an estimated revenue figure of 23.09M for the next ending quarter. Year-ago sales stood 139k and 40k respectively for this quarter and the next, and analysts expect sales will grow by 6,738.31% for the current quarter and 3,312.86% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 1.17% over the past 5 years. Earnings growth for 2025 is a modest 30.43% while over the next 5 years, the company’s earnings are expected to increase by 32.58%.
IBRX Dividends
ImmunityBio Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
Insiders own 73.52% of the company shares, while shares held by institutions stand at 11.55% with a share float percentage of 43.61%. Investors are also buoyed by the number of investors in a company, with ImmunityBio Inc having a total of 276.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 13.83 million shares worth more than $87.42 million. As of 2024-06-30, VANGUARD GROUP INC held 2.0558% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 11.42 million shares as of 2024-06-30. The firm’s total holdings are worth over $72.19 million and represent 1.6978% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF . As of Sep 30, 2024 , the former fund manager holds about 0.82% shares in the company for having 5.72 shares of worth $20.7 million while later fund manager owns 4.98 shares of worth $18.01 million as of Nov 30, 2024 , which makes it owner of about 0.71% of company’s outstanding stock.
